Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis

References

• Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. 2008;9(7):517–531.
   PubMed Web of Science ®Google Scholar
• Spencer-Smith R, O’Bryan JP. Direct inhibition of RAS: quest for the Holy Grail? Semin Cancer Biol. 2019;54:138–148.
   PubMed Web of Science ®Google Scholar
• Cox AD, Der CJ. Ras history: the saga continues. Small GTPases. 2010;1(1):2–27.
   PubMedGoogle Scholar
• Simanshu DK, Nissley DV, McCormick F RAS Proteins and Their Regulators in Human Disease. Cell 2017;170(1):17–33
   PubMed Web of Science ®Google Scholar
• Vigil D, Cherfils J, Rossman KL, et al. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer. 2010;10(12):842–857.
   PubMed Web of Science ®Google Scholar
• Cherfils J, Zeghouf M. Regulation of small GTPases by GEFs, GAPs, and GDIs. Physiol Rev. 2013;93(1):269–309.
   PubMed Web of Science ®Google Scholar
• Cox AD, Fesik SW, Kimmelman AC, et al. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13(11):828–851.
   PubMed Web of Science ®Google Scholar
• Zuberi M, Khan I, O’Bryan JP. Inhibition of RAS: proven and potential vulnerabilities. Biochem Soc Trans. 2020;48(5):1831–1841.
   PubMed Web of Science ®Google Scholar
• Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell Sci. 2016;129(7):1287–1292.
   PubMed Web of Science ®Google Scholar
• Targeting DJ. RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11–22.
   PubMed Web of Science ®Google Scholar
• O’Bryan JP. Pharmacological targeting of RAS: recent success with direct inhibitors. Pharmacol Res. 2018;139:503–511.
   PubMed Web of Science ®Google Scholar
• Ostrem JM, Shokat KM. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov. 2016;15(11):771–785.
   PubMed Web of Science ®Google Scholar
• Lito P, Solomon M, Li LS, et al. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2016;351(6273):604–608.
   PubMed Web of Science ®Google Scholar
• Janes MR, Zhang J, Li L-S, et al. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell. 2018;172(3):578–589. e17.
   PubMed Web of Science ®Google Scholar
• Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217–223.
   PubMed Web of Science ®Google Scholar
• Hallin J, Engstrom LD, Hargis L, et al. The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discov. 2020;10(1):54–71.
   PubMed Web of Science ®Google Scholar
• Sha F, Salzman G, Gupta A, et al. Monobodies and other synthetic binding proteins for expanding protein science. Protein Sci. 2017;26(5):910–924.
   PubMed Web of Science ®Google Scholar
• Koide A, Koide S. Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol Biol. 2007;352:95–109. [pii].
   PubMedGoogle Scholar
• Koide A, Wojcik J, Gilbreth RN, et al. Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold. [pii]10.1016/j.jmb.2011.12.019 J Mol Biol. 2012;4151:393–405.
   PubMedGoogle Scholar
• Spencer-Smith R, Koide A, Zhou Y, et al. Inhibition of RAS function through targeting an allosteric regulatory site. Nat Chem Biol. 2017;13(1):62–68.
   PubMed Web of Science ®Google Scholar
• Spencer-Smith R, Li L, Prasad S, et al. Targeting the alpha4-alpha5 interface of RAS results in multiple levels of inhibition. 0 Small GTPases. 2017;105:378–387.
   PubMedGoogle Scholar
• Khan I, Spencer-Smith R, O’Bryan JP. Targeting the α4-α5 dimerization interface of K-RAS inhibits tumor formation in vivo. Oncogene. 2018. 10.1038/s41388-018-0636-y
   Web of Science ®Google Scholar
• Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7(5):469–483.
   PubMed Web of Science ®Google Scholar
• McCormick F. Sticking it to KRAS: covalent Inhibitors Enter the Clinic. Cancer Cell. 2020;37(1):3–4.
   PubMed Web of Science ®Google Scholar
• Bonaventura P, Shekarian T, Alcazer V, et al. Cold Tumors: a Therapeutic Challenge for Immunotherapy. Front Immunol. 2019;10:168.
   PubMed Web of Science ®Google Scholar
• Coelho MA, De Carné Trécesson S, Rana S, et al. Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA. Immunity. 2017;47(6):1083–99.e6.
   PubMed Web of Science ®Google Scholar
• Briere DM. The KRASG12C inhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination with anti-PD-1 therapy in a syngeneic mouse model. Mol Cancer Ther. 2019. Dec 2019. Published. 10.1158/1535-7163.TARG-19-LB-C09
   Web of Science ®Google Scholar
• Khan I, Rhett JM, O’Bryan JP. Therapeutic targeting of RAS: new hope for drugging the “undruggable”. Biochim Biophys Acta Mol Cell Res. 2020;1867(2):118570.
   PubMed Web of Science ®Google Scholar
• Moore AR, Rosenberg SC, McCormick F, et al. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. 2020;19(8):533–552.
   PubMed Web of Science ®Google Scholar
• Rhett JM, Khan I, O’Bryan JP. Biology, pathology, and therapeutic targeting of RAS. Adv Cancer Res. 2020;148:69–146.
   PubMed Web of Science ®Google Scholar
• Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72(10):2457–2467.
   PubMed Web of Science ®Google Scholar
• Fell JB, Fischer JP, Baer BR, et al. Identification of the Clinical Development Candidate MRTX849, a Covalent KRAS(G12C) Inhibitor for the Treatment of Cancer. J Med Chem. 2020;63(13):6679–6693.
   PubMed Web of Science ®Google Scholar
• Linnemann C, Van Buuren MM, Bies L, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med. 2015;21(1):81–85.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Vormehr M, Van De Roemer N, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015;520(7549):692–696.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–221.
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–226.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yu X, Zheng L, et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature. 2018;564(7735):268–272.
   PubMed Web of Science ®Google Scholar
• Galaine J, Turco C, Vauchy C, et al. CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin. Int J Cancer. 2019;145(11):3112–3125.
   PubMed Web of Science ®Google Scholar
• Tay RE, Richardson EK, Toh HC. Revisiting the role of CD4(+) T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther. 2020;28(1–2):5–17.
   PubMed Web of Science ®Google Scholar
• Liao W, Overman MJ, Boutin AT, et al. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019;35(4):559–572. e7.
   PubMed Web of Science ®Google Scholar
• Poulin EJ, Bera AK, Lu J, et al. Tissue-Specific Oncogenic Activity of KRAS A146T. Cancer Discov. 2019;9(6):738–755.
   PubMed Web of Science ®Google Scholar
• Hobbs GA, Baker NM, Miermont AM, et al. Atypical KRAS(G12R) Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer Discov. 2020;10(1):104–123.
   PubMed Web of Science ®Google Scholar
• Ambrogio C, Köhler J, Zhou Z-W, et al. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell. 2018;172(4):857–868. e15.
   PubMed Web of Science ®Google Scholar
• Bery N, Legg S, Debreczeni J, et al. KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe. Nat Commun. 2019;10(1):2607.
   PubMedGoogle Scholar
• Sutton MN, Lu Z, Li YC, et al. DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters. Cell Rep. 2019;29(11):3448–59.e6.
   PubMed Web of Science ®Google Scholar
• Kordiak J, Szemraj J, Grabska-Kobylecka I, et al. Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate. J Cancer Res Clin Oncol. 2019;145(1):241–251.
   PubMed Web of Science ®Google Scholar
• Lamy A, Blanchard F, Le Pessot F, et al. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Mod Pathol. 2011;24(8):1090–1100.
   PubMed Web of Science ®Google Scholar
• Richman SD, Chambers P, Seymour MT, et al. Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal Cell Pathol (Amst). 2011;34(1–2):61–66.
   PubMedGoogle Scholar
• Kunkel TA, Roberts JD, Zakour RA. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 1987;154:367–382.
   PubMed Web of Science ®Google Scholar
• Clark G, Cox AD, Graham SM, et al. Biological assays for Ras transformation. Methods Enzymol. 1995;255:395–412.
   PubMed Web of Science ®Google Scholar
• Pitarresi JR, Liu X, Avendano A, et al. Disruption of stromal hedgehog signaling initiates RNF5-mediated proteasomal degradation of PTEN and accelerates pancreatic tumor growth. Life Sci Alliance. 2018;1(5):e201800190.
   PubMed Web of Science ®Google Scholar
• He K, Gkioxari G, Dollár P, et al. Mask r-cnn. arXiv:1703.06870v3
   Google Scholar
• He K, Zhang X, Ren S, et al. Deep residual learning for image recognition. CVPR Conference 2016. p. 770–778. New York City: IEEE.
   Google Scholar
• Lin T-Y, Maire M, Belongie S. et al. Microsoft coco: common objects in context. arXiv:1405.0312v3
   Google Scholar
• Schindelin J, Rueden CT, Hiner MC, et al. The ImageJ ecosystem: an open platform for biomedical image analysis. Mol Reprod Dev. 2015;82(7–8):518–529.
   PubMed Web of Science ®Google Scholar
• Ollion J, Cochennec J, Loll F, et al. TANGO: a generic tool for high-throughput 3D image analysis for studying nuclear organization. Bioinformatics. 2013;29(14):1840–1841.
   PubMed Web of Science ®Google Scholar